What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Lung cancer, Oncology, Surgery and Cancer are his primary areas of study.
His Internal medicine study frequently draws connections to other fields, such as Gastroenterology.
He has researched Lung cancer in several fields, including Chemotherapy, Carboplatin, Survival rate, Randomized controlled trial and Radiation therapy.
His Oncology research incorporates themes from Phases of clinical research, Proportional hazards model, Docetaxel, Bevacizumab and Gemcitabine.
His work deals with themes such as Hazard ratio, Quality of life and Gefitinib, which intersect with Surgery.
The Cancer study combines topics in areas such as Carcinoma, Clinical trial, Pathology, Intensive care medicine and Propensity score matching.
His most cited work include:
- Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. (3774 citations)
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial (2280 citations)
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study (927 citations)
What are the main themes of his work throughout his whole career to date?
Chandra P. Belani mainly focuses on Internal medicine, Oncology, Lung cancer, Chemotherapy and Surgery.
His studies deal with areas such as Regimen, Gemcitabine, Radiation therapy and Cisplatin as well as Oncology.
The Lung cancer study which covers Carcinoma that intersects with Adenocarcinoma.
His research in Chemotherapy intersects with topics in Taxane and Clinical trial.
His Surgery study integrates concerns from other disciplines, such as Gastroenterology and Urology.
While the research belongs to areas of Carboplatin, he spends his time largely on the problem of Paclitaxel, intersecting his research to questions surrounding Pharmacokinetics.
He most often published in these fields:
- Internal medicine (70.94%)
- Oncology (60.29%)
- Lung cancer (55.05%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (70.94%)
- Lung cancer (55.05%)
- Oncology (60.29%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Lung cancer, Oncology, Cancer and Cancer research.
Chandra P. Belani combines subjects such as Gastroenterology and Surgery with his study of Internal medicine.
Particularly relevant to Carboplatin is his body of work in Surgery.
His studies in Lung cancer integrate themes in fields like Targeted therapy, Lung, Disease, Hazard ratio and Radiation therapy.
His Oncology research also works with subjects such as
- Taxane which is related to area like Survival rate,
- Clinical endpoint which connect with Phases of clinical research.
His Cancer research includes elements of Immunology, T cell, Immune system and Carcinoma.
Between 2014 and 2021, his most popular works were:
- Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature (141 citations)
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer (100 citations)
- Rapid magnetic isolation of extracellular vesicles via lipid-based nanoprobes. (73 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary scientific interests are in Lung cancer, Internal medicine, Oncology, Cancer and Surgery.
The study incorporates disciplines such as Regimen, Immunology, Targeted therapy, Radiation therapy and Genetic testing in addition to Lung cancer.
His Regimen research is multidisciplinary, incorporating perspectives in Survival rate and Docetaxel.
His study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology.
His Oncology study combines topics from a wide range of disciplines, such as Taxane, Etoposide, Clinical endpoint, Randomized controlled trial and Bevacizumab.
Many of his research projects under Surgery are closely connected to Rivaroxaban and Risk assessment with Rivaroxaban and Risk assessment, tying the diverse disciplines of science together.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
